MSH2 and neoplasm: Patients whose tumor samples expressed low MSH2 had not reached the median OS at the time of follow-up, compared to patients whose tumor samples expressed high MSH2 (60.5 months [44.6–77.8]) (Figure 3, left panel), in both univariate (HR = 0.65 [0.48 to 0.89], log-rank p = 0.007) and multivariate analysis (Cox model, including stage, histology, and gender, adjusted HR = 0.66, 95% CI [0.48-0.90], p = 0.008) (Table 2).